Alethia Biotherapeutics Inc.
Founded 2002 · 12 employees on LinkedIn · 13 known investors
Find your way into Alethia Biotherapeutics Inc.
Sign up to see every warm intro you have to Alethia Biotherapeutics Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Alethia Biotherapeutics Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Alethia Biotherapeutics is a clinical-stage biotechnology company developing cancer treatments that target tumor resistance by inhibiting the epithelial-mesenchymal transition (EMT) and remodeling the immunosuppressive tumor microenvironment. Its lead asset, sotevtamab, is a monoclonal antibody intended to be combined with standard therapies across multiple cancer indications.
Investors · 13
How we know: BDC Climate Tech Fund II's portfolio page · Not right? Tell us
How we know: BDC Fund Investments (Fund-of-Funds)'s portfolio page · Not right? Tell us
How we know: BDC Growth Venture Fund's portfolio page · Not right? Tell us
How we know: BDC Industrial Innovation Venture Fund's portfolio page · Not right? Tell us
How we know: BDC Seed Venture Fund's portfolio page · Not right? Tell us
How we know: BDC Sustainability Venture Fund's portfolio page · Not right? Tell us
How we know: BDC Thrive Lab for Women's portfolio page · Not right? Tell us
How we know: BDC Thrive Venture Fund for Women's portfolio page · Not right? Tell us
How we know: funding news · biospace.com · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · biospace.com · Not right? Tell us
Also in the syndicate · 2
Funding
SEC filings, press & company announcements- Undisclosed amountSeries ASep 2010
AgeChem Venture Fund (lead), BDC Venture Capital (lead), Epicentre Technologies Corporation, GO Capital
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Alethia Biotherapeutics Inc. do?
- Alethia Biotherapeutics is a clinical-stage biotechnology company developing cancer treatments that target tumor resistance by inhibiting the epithelial-mesenchymal transition (EMT) and remodeling the immunosuppressive tumor microenvironment. Its lead asset, sotevtamab, is a monoclonal antibody intended to be combined with standard therapies across multiple cancer indications.
- Who are Alethia Biotherapeutics Inc.'s investors?
- Alethia Biotherapeutics Inc.'s investors include BDC Climate Tech Fund II, BDC Fund Investments (Fund-of-Funds), BDC Growth Venture Fund, BDC Industrial Innovation Venture Fund, BDC Seed Venture Fund, BDC Sustainability Venture Fund, BDC Thrive Lab for Women, BDC Thrive Venture Fund for Women and 3 more.


